Cancer biotech Inhibrx files for a $75 million IPO

Inhibrx, which is using protein engineering to develop targeted therapies for cancer and rare diseases, filed on Monday with the SEC to raise up to $75 million in an initial public offering.

The La Jolla, CA-based company was founded in 2010 and booked $14 million in revenue for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol INBX. Inhibrx filed confidentially on January 7, 2019. Evercore ISI, Barclays and Nomura Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cancer biotech Inhibrx files for a $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest IPOs Videos

    McAfee Corp. Rings the Nasdaq Stock Market Opening Bell in Celebration of its IPO

    McAfee Corp. (Nasdaq: MCFE), the device-to-cloud cybersecurity company, rings the Nasdaq Opening Bell remotely from across the country. Peter Leav, CEO, rings the Opening Bell alongside the Company’s team in a virtual bell ringing ceremony.

    Oct 22, 2020

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More